Introducing the Recipients of the Incyte Ingenuity Awards in GVHD

Congratulations, Cincinnati Children’s Hospital Medical Center and Children’s Healthcare of Atlanta!

Introducing the 2022 Recipients of the Incyte Ingenuity Awards in GVHD!

Cincinnati Children’s Hospital Medical Center logo

Cincinnati Children’s Hospital Medical Center

Cincinnati Children’s Hospital Medical Center has been awarded $100,000 to implement its project, The Impact of Chronic GVHD on Academic Performance in Children and Young Adults.

This study will assess the specific barriers to academic performance in children and young adults of school/college going ages with chronic GVHD. The study will evaluate the academic performance of 20 individuals with chronic GVHD and compare them against 20 peers without chronic GVHD.

Once barriers are identified, the initiative will generate targeted interventions that address these gaps in educational resources for these children and young adults.

Aflac Cancer & Blood Disorders Center – Children's' Healthcare of Atlanta logo

Children’s Healthcare of Atlanta

Children’s Healthcare of Atlanta has been awarded $35,000 to implement its project A Virtual Rehabilitation Program for Children With Chronic GVHD.

The virtual rehabilitation program aims to provide easy access to physical fitness to improve exercise adherence, aerobic capacity, musculoskeletal strength and flexibility, and ultimately, quality of life in children living with chronic GVHD. Studies have shown that physical rehabilitation is often inadequately addressed in comprehensive chronic GVHD care. This proposal will address the need for physical rehabilitation for these children and tackle limiting barriers they face, such as exposure and risk of infection, given the virtual environment.

The 2022 recipients, Cincinnati Children’s Hospital Medical Center and Children’s Healthcare of Atlanta, were selected as their projects embodied the core mission of the Incyte Ingenuity Awards in GVHD. Both offered innovative and unwavering commitment to improving the lives of those living with GVHD.

We look forward to seeing these proposals come to fruition and the positive impact they will have on the GVHD community. Interested in learning about past winning projects? Click on the 2020 or 2021 tabs to read about the previous award recipients!

The 2021 Recipients of the Incyte Ingenuity Awards in GVHD

Memorial Sloan Kettering Cancer Center logo

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center was awarded $100,000 to implement its project, the GVHD-Focused Telehealth Clinic.

The GVHD-Focused Telehealth Clinic will address inequities and expand access to GVHD care, by creating a multispecialty GVHD telehealth clinic for adult and pediatric patients with GVHD. This telehealth clinic aims to improve patient access to GVHD management and thereby improve their quality of life. The project also aims not only to improve access, by serving a wider and more diverse population of people with GVHD, but also to decrease GVHD-associated complications.

Aplastic Anemia and MDS International Foundation logo

Aplastic Anemia and MDS International Foundation

Aplastic Anemia and MDS International Foundation was awarded $35,000 to implement its project, GVHD Interactive Provider Network.

GVHD Interactive Provider Network will address the need for expert advice and mentoring by creating a space for disease specialists to connect with community-based providers. Through this network, these healthcare providers will be able to share expertise and discuss cases in order to improve care for patients with chronic GVHD, especially in practices outside of major academic centers. The Aplastic Anemia and MDS International Foundation will tackle this project by using proven adult learning techniques and interactive video technology in real-time collaborative sessions to help healthcare professionals gain the expertise required to provide needed services.

Both the GVHD-Focused Telehealth Clinic and GVHD Interactive Provider Network were selected by the judges because they embody the core mission of the Incyte Ingenuity Awards in GVHD program in fostering collaboration with the GVHD community to improve the lives of those living with GVHD.

In particular, the judges noted that the GVHD-Focused Telehealth Clinic demonstrated a high potential impact for the GVHD community by ensuring GVHD patients and their caregivers from all backgrounds are able to access advanced GVHD providers through a telehealth platform. Meanwhile, the GVHD Interactive Provider Network was selected as the judges deemed that the goal of transferring knowledge in managing GVHD is a worthy and valuable cause that tackles concerns of inequitable care that some GVHD patients may face.

The Inaugural Recipient of the Incyte Ingenuity Award in GVHD

Massachusetts General Hospital Cancer Center logo

Massachusetts General Cancer Center

In September of 2020, Massachusetts General Cancer Center was awarded $100,000 to implement its project, Horizon Mobile App for Patients with GVHD.

This project will develop a patient-centered, multi-component mobile intervention app that aims to improve the quality of life and care of patients with chronic GVHD. The app will consist of an educational game, which will allow a patient character to navigate through a journey as they cope with their chronic GVHD and monitor their progress. The effectiveness of this app will be evaluated via a pilot program, with consideration for a larger expansion.

Horizon Mobile App for Patients with Chronic GVHD was selected by the judges because it embodies the core mission of the Incyte Ingenuity Awards in GVHD program in fostering collaboration with the community to improve the lives of those living with GVHD.

In particular, the judges noted that this project was the most well-developed application with a clear objective and realistic approach to improving the GVHD patient experience.

Since being awarded, Massachusetts General Cancer Center successfully piloted their app and is now seeking FDA approval to continue to use it as a therapeutic agent.

2020 award recipient, Areej El-Jawahri, MD, explains her award-winning project and her experience working with GVHD patients.